205 related articles for article (PubMed ID: 21556366)
1. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Skjønsberg G; Aas T; Schlichting E; Fjösne HE; Nysted A; Lillehaug JR; Lønning PE
PLoS One; 2011 Apr; 6(4):e19249. PubMed ID: 21556366
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Okishiro M; Kim SJ; Tsunashima R; Nakayama T; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Apr; 132(3):947-53. PubMed ID: 21706156
[TBL] [Abstract][Full Text] [Related]
3. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
4. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
7. Association of the
Miedl H; Lebhard J; Ehart L; Schreiber M
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
[TBL] [Abstract][Full Text] [Related]
8. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
9. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
10. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.
Ohnstad HO; Castro R; Sun J; Heintz KM; Vassilev LT; Bjerkehagen B; Kresse SH; Meza-Zepeda LA; Myklebost O
Cancer; 2013 Mar; 119(5):1013-22. PubMed ID: 23165797
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients.
Yadav P; Masroor M; Tanwer K; Mir R; Javid J; Ahmad I; Zuberi M; Kaza RC; Jain SK; Khurana N; Ray PC; Saxena A
Clin Transl Oncol; 2016 Jul; 18(7):728-34. PubMed ID: 26553387
[TBL] [Abstract][Full Text] [Related]
12. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Sinilnikova OM; Antoniou AC; Simard J; Healey S; Léoné M; Sinnett D; Spurdle AB; Beesley J; Chen X; ; Greene MH; Loud JT; Lejbkowicz F; Rennert G; Dishon S; Andrulis IL; ; Domchek SM; Nathanson KL; Manoukian S; Radice P; Konstantopoulou I; Blanco I; Laborde AL; Durán M; Osorio A; Benitez J; Hamann U; Hogervorst FB; van Os TA; Gille HJ; ; Peock S; Cook M; Luccarini C; Evans DG; Lalloo F; Eeles R; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Brewer C; ; Hughes DJ; Coupier I; Giraud S; Coulet F; Colas C; Soubrier F; Rouleau E; Bièche I; Lidereau R; Demange L; Nogues C; Lynch HT; ; Schmutzler RK; Versmold B; Engel C; Meindl A; Arnold N; Sutter C; Deissler H; Schaefer D; Froster UG; ; Aittomäki K; Nevanlinna H; McGuffog L; Easton DF; Chenevix-Trench G; Stoppa-Lyonnet D;
Br J Cancer; 2009 Oct; 101(8):1456-60. PubMed ID: 19707196
[TBL] [Abstract][Full Text] [Related]
13. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
14. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.
Toyama T; Zhang Z; Nishio M; Hamaguchi M; Kondo N; Iwase H; Iwata H; Takahashi S; Yamashita H; Fujii Y
Breast Cancer Res; 2007; 9(3):R34. PubMed ID: 17537232
[TBL] [Abstract][Full Text] [Related]
15. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast.
Sonnenberg M; van der Kuip H; Haubeis S; Fritz P; Schroth W; Friedel G; Simon W; Mürdter TE; Aulitzky WE
BMC Cancer; 2008 Dec; 8():364. PubMed ID: 19077243
[TBL] [Abstract][Full Text] [Related]
16. A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.
Sanchez-Carbayo M; Socci ND; Kirchoff T; Erill N; Offit K; Bochner BH; Cordon-Cardo C
Clin Cancer Res; 2007 Jun; 13(11):3215-20. PubMed ID: 17545525
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
Olsson H; Hultman P; Rosell J; Söderkvist P; Jahnson S
BMC Urol; 2013 Jan; 13():5. PubMed ID: 23356517
[TBL] [Abstract][Full Text] [Related]
18. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
19. Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.
Cheng H; Ma B; Jiang R; Wang W; Guo H; Shen N; Li D; Zhao Q; Wang R; Yi P; Zhao Y; Liu Z; Huang T
Mol Biol Rep; 2012 Sep; 39(9):9265-74. PubMed ID: 22729912
[TBL] [Abstract][Full Text] [Related]
20. MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Vivenza D; Gasco M; Monteverde M; Lattanzio L; Syed N; Colantonio I; Denaro N; Natoli G; Comino A; Russi E; Merlano M; Crook T; Lo Nigro C
Oral Oncol; 2012 Jul; 48(7):602-7. PubMed ID: 22356895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
